Chylomicron remnant: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chylomicron remnant}} | {{Chylomicron remnant}} | ||
{{CMG | {{CMG}} | ||
== [[Chylomicron remnant overview|Overview]] == | == [[Chylomicron remnant overview|Overview]] == | ||
| Line 25: | Line 25: | ||
{{Lipoproteins}} | {{Lipoproteins}} | ||
[[Category:Cardiology]] | |||
[[Category:Lipid disorders]] | [[Category:Lipid disorders]] | ||
[[Category:Lipoproteins]] | [[Category:Lipoproteins]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:13, 12 September 2013
|
Chylomicron Remnant Microchapters |
|
Clinical Correlation |
|---|
|
Treatment |
|
Case Studies |
|
Chylomicron remnant On the Web |
|
American Roentgen Ray Society Images of Chylomicron remnant |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
Classification
Biochemistry
Physiology
Clinical Correlation
High Chylomicron Remnant
Epidemiology and Demographics | Pathophysiology | Causes | Diseases | Prognosis and Complications
Low Chylomicron Remnant
Epidemiology and Demographics | Pathophysiology | Causes | Diseases | Prognosis and Complications
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Landmark Trials | Future or Investigational Therapies